Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 24, 2026

SK pharmteco und Prozomix geben strategische Zusammenarbeit bekannt, um die Biokatalyse-Kompetenzen für die weltweite Arzneimittelherstellung zu stärken

View original at globenewswire.com
SK pharmteco und Prozomix geben strategische Zusammenarbeit bekannt, um die Biokatalyse-Kompetenzen für die weltweite Arzneimittelherstellung zu stärken RANCHO CORDOVA, Kalifornien, March 24, 2026 (GLOBE NEWSWIRE) -- SK pharmteco, ein weltweit führendes Auftragsentwicklungs- und Produktionsunternehmen (CDMO), und Prozo…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Prozomix is very pleased to collaborate with a globally leading CDMO provider like SK pharmteco to ensure the full potential of their enzyme portfolio is realized in the most demanding pharmaceutical applications

    60% confidence

  • Integrating Prozomix's enzyme diversity into SK pharmteco's global research, development, and production workflows complements existing technology platforms and enables the company to offer customers more innovative and sustainable solutions

    60% confidence

  • Prozomix's ability to rapidly deploy large quantities of optimized enzymes, combined with SK pharmteco's outstanding manufacturing expertise, guarantees customers can transition from research phase to commercial production with unmatched speed and reliability

    60% confidence

  • Prozomix has made a name globally by minimizing risks in the early phase of bioprocess development through its highly diverse enzyme panels and rapid scaling capabilities

    60% confidence

  • As drug molecules become increasingly complex, the use of enzymes offers a more environmentally friendly, selective, and cost-effective alternative to traditional chemical synthesis

    60% confidence

  • At SK pharmteco, our mission is to build close relationships with industry leaders based on trust, quality, and shared commitment to reliably deliver medicines to the highest standards

    60% confidence

Cited in these Via News reports